Brief: Vor Biopharma Says 100% Patients On Telitacicept Achieve ≥2-Point MG-ADL Improvement
29/10/2025 15:44
Oct 29 (Reuters) - Vor Biopharma Inc VOR.O: TELITACICEPT DEMONSTRATES SUSTAINED EFFICACY AND FAVORABLE SAFETY PROFILE IN 48-WEEK CHINA PHASE 3 OPEN-LABEL EXTENSION GENERALIZED MYASTHENIA GRAVIS DATA VOR BIOPHARMA INC - 100% PATIENTS ON TELITACICEPT ACHIEVE ≥2-POINT MG-ADL IMPROVEMENT VOR BIOPHARMA INC - NO INJECTION SITE REACTIONS IN TELITACICEPT PATIENTS VOR BIOPHARMA INC - TELITACICEPT SHOWS FAVORABLE PROFILE COMPARED TO PLACEBO Source text: ID:nGNX7GVk07 Further company coverage: VOR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vor Biopharma
See all newsBrief: Telitacicept Demonstrates Durable Preservation Of Kidney Function Through Two Years In Phase 3 Teligan Trial In Iga Nephropathy
Vor Bio says its experimental drug slowed loss of kidney function in late-stage study
U.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning